Equipoise 500

Boldenone Undecylenate — Equipoise 500 by Dragon Pharma

Equipoise 500 is Dragon Pharma's high-concentration formulation of injectable Boldenone Undecylenate at 500mg/ml — the same active substance and ester as EQ 300, at a significantly higher concentration for advanced users running higher weekly doses across extended 14-16 week cycles. Each 10ml vial in Dragon Pharma's MCT oil carrier delivers the same compound at a concentration that meaningfully reduces injection volume at higher weekly doses.

Also searched as: Boldenone 500mg, Equipoise 500mg, high-dose EQ, Equipoise 500 Dragon Pharma.

What Is Equipoise 500?

Equipoise 500 contains Boldenone Undecylenate — structurally testosterone with a C1-C2 double bond, producing a compound with approximately 50% of testosterone's androgenic activity, 50% of its aromatisation rate, and significantly stronger erythropoietic (RBC-stimulating) effects. The 500mg/ml concentration is the only meaningful difference from EQ 300 — the same extended 14-day half-life, the same cycle length requirements and the same monitoring considerations apply. For full compound background, see the EQ 300 product page.

Why Higher Concentration Matters for Long EQ Cycles

The practical case for Equipoise 500 over EQ 300 is more compelling for Boldenone than for most other compounds, specifically because of EQ's cycle length requirements:

• A 16-week EQ cycle at 600mg/week requires 9.6ml per week at 300mg/ml vs 1.2ml per week at 500mg/ml — a 5× reduction in volume per injection
• Over a full 16-week cycle, this translates to a significantly lower total injection volume and fewer injection site rotations
• EQ is already one of the more viscous injectable compounds — at 500mg/ml in MCT oil, warming the vial before drawing is particularly important to maintain flowability

Effects and Benefits

• Steady lean mass gains with lower water retention than testosterone at equivalent doses
• Pronounced appetite stimulation — one of the strongest of any AAS, useful in caloric surplus phases
• Improved endurance and work capacity through RBC/haematocrit elevation
• High concentration reduces injection volume across extended 14-16 week protocols
• Lower androgenic activity and aromatisation rate than testosterone

Dosage and Administration

Weekly doses are split into 2 injections to maintain more stable blood levels despite the long half-life. Due to the high concentration, warming the vial gently before drawing is recommended to improve viscosity and reduce injection site discomfort.